

**BIOFIL CHEMICALS & PHARMACEUTICALS LTD.**

11/12, Sector-E, Sanwer Road, Industrial Area, Indore- 452 015. Fax : 0731-2723017
Tel. : 0731 - 2723016, 4065516 Email : biofilchemicals@yahoo.com
Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)
Tel. : 0731-4011700, 2420926, 2424003, 2423435 Fax : 4011740

To
The Secretary,
The National Stock Exchange of India Limited
Bandra Kurla Complex
Mumbai

To
The Secretary,
The Bombay Stock Exchange Limited
P.J. Tower, Dalal Street
Mumbai

Dated: 13th February, 2012

Dear Sir,

Sub: Un-Audited Financial Results for the quarter ended on 31st December 2011.

In compliance with clause 41 of the listing agreement, we are submitting herewith the Un-audited financial results for the quarter ended 31st December 2011.

Please find the same and oblige.

Thanking you,

Yours Faithfully

For Biofil Chemicals & Pharmaceuticals Ltd.


Authorised Signatory

Encl : a/a

Unaudited Financial Results (Provisional) of Quarter Ended Dec. 2011
31-12-2011 of M/s. Biofil Chemicals & Pharmaceuticals Limited
11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

(Rs. In Lacs)

S. No.	Particulars	Three months ended 31-12-11	Three months ended 30/09/11	Corresponding three months ended in the previous Year 31-12-10	Year to date figures for current period ended 31/12/11	Year to date figures for the previous year ended 31/12/10	Previous accounting year ended 31/03/2011
		Revised	Revised	Revised	Revised	Revised	Audited
1	(a) Net Sales/Income from Operations	30.27	21.84	110.99	112.67	195.03	215.21
	(b) Other Operating Income	6.28	7.29	1.05	27.33	3.15	60.80
	Total	36.55	29.13	112.04	140.00	198.18	276.01
2	Expenditure						
	a. (Increase)/decrease in stock in trade and work in progress	2.50	(12.15)	(0.72)	(12.40)	(3.52)	0.00
	b. Consumption of raw materials	8.74	4.22	9.52	55.35	9.52	17.51
	c. Purchase of traded goods	4.74	12.31	88.12	30.35	160.33	178.98
	d. Employees cost	2.55	3.52	2.15	9.03	2.15	16.90
	e. Depreciation	3.84	3.84	2.67	11.52	8.01	15.34
	f. Other expenditure	9.59	7.69	7.53	27.14	19.62	81.38
	g. Total	31.97	19.43	109.27	121.00	196.11	310.11
	(Any item exceeding 10% of the total expenditure to be shown separately) (preliminary exp. 1/5 written off)						31.50
3	Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	4.58	9.70	2.77	19.00	2.07	(65.60)
4	Other Income						165.65
5	Profit before Interest and Exceptional Items (3+4)	4.58	9.70	2.77	19.00	2.07	100.05
6	Interest	1.11	2.75	0	5.16	0.00	0.91
7	Profit after Interest but before Exceptional Items (5-6)						
8	Exceptional items						
9	Profit (+)/ Loss (-) from Ordinary Activities before tax (7+8)	3.47	6.95	2.77	13.84	2.07	99.14
10	Tax expense						
	- Income Tax - MAT						
	- Fringe Benefit Tax						
11	Net Profit (+)/ Loss (-) from ordinary Activities after Tax (09-10)	3.47	6.95	2.77	13.84	2.07	99.14
12	Extraordinary Item (net of tax expense Rs.)						
13	Net Profit(+)/ Loss(-) for the period (11-12)	3.47	6.95	2.77	13.84	2.07	99.14
14	Paid-up equity share capital	1627.38	1627.38	1056.13	1627.38	1056.13	1627.38
	(Face Value of the Share shall be indicated)						
15	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year						1284.42
16	Earnings Per Share (EPS)						
	a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	0.0021	0.0043	0.0026	0.0085	0.0020	0.061
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	0.0021	0.0043	0.0026	0.0085	0.0020	0.061
17	Public Shareholding						
	- No. of shares	8655100	8655100	6105100	8655100	6105100	8655100
	- Percentage of shareholding	53.18	53.18	57.81	53.18	57.81	53.18

1. The above statement of financial result was approved by the board of directors at their meeting held on 13-02-2012
2. The company is engaged in manufacture of Drugs, Pharmaceuticals & Chemicals as such there are no separate reportable segment as per accounting standard 17.
3. The unaudited financial result (Provisional) for the quarter ended on 31-12-2011 has been reviewed by the statutory auditor.
4. The figures have been regrouped wherever necessary.
5. The deferred Tax will be calculated at the end of financial year.
6. During the quarter one Compliant was received and same was resoved, hence no complaint was pending for this quarter.
7. During the quarter sales have been decreased due to renovation work for CGMP factory situated at Sawner Road Indore.

[illegible]